Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Background/Aim First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. Patients...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2017-02, Vol.19 (2), p.219-226
Main Authors: De Castro, J., González-Larriba, J. L., Vázquez, S., Massutí, B., Sanchez-Torres, J. M., Dómine, M., Garrido, P., Calles, A., Artal, A., Collado, R., García, R., Sereno, M., Majem, M., Macías, J. A., Juan, O., Gómez-Codina, J., Hernández, B., Lázaro, M., Ortega, A. L., Cobo, M., Trigo, J. M., Carcereny, E., Rolfo, C., Macia, S., Muñoz, J., Diz, P., Méndez, M., Rosillo, F., Paz-Ares, L., Cardona, J. V., Isla, D.
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Aged
Angiogenesis Inhibitors - therapeutic use
Bevacizumab - therapeutic use
Carcinoma, Large Cell - drug therapy
Carcinoma, Large Cell - mortality
Carcinoma, Large Cell - pathology
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Female
Follow-Up Studies
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasm Staging
Oncology
Prognosis
Research Article
Retrospective Studies
Survival Rate
Survivors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. Patients and methods This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. Results Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. Conclusion Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-016-1527-8